PA
BLTE

Perceptive Advisors’s Belite Bio BLTE Stock Holding History

Perceptive Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-151,979
Closed -$24.2M – 111
2026
Q1 		$24.2M Sell
151,979
-262,260
-63% -$44.1M 0.47% 47
2025
Q4 		$66.3M Buy
414,239
+364,451
+732% +$43.2M 1.18% 29
2025
Q3 		$3.68M Buy
+49,788
New +$3.27M 0.11% 75

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors's BLTE Position: Q2 2026 in Review

Perceptive Advisors sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 151,979 shares — an estimated $24.2M sold.

Perceptive Advisors first reported a position in BLTE in Q3 2025 and held it in 3 quarters. The position peaked at $66.3M in Q4 2025. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Perceptive Advisors reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
  • Perceptive Advisors sold 151,979 Belite Bio shares in Q2 2026, an estimated $24.2M.
  • Perceptive Advisors first reported a position in Belite Bio in Q3 2025 and held it in 3 quarters.
  • Perceptive Advisors's Belite Bio position peaked at $66.3M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.